EE666 Cost-Effectiveness of Duvelisib Versus the Bendamustine Plus Rituximab Regimen for Relapsed/Refractory Follicular Lymphoma Patients in China
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.931
https://www.valueinhealthjournal.com/article/S1098-3015(23)04061-5/fulltext
Title :
EE666 Cost-Effectiveness of Duvelisib Versus the Bendamustine Plus Rituximab Regimen for Relapsed/Refractory Follicular Lymphoma Patients in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04061-5&doi=10.1016/j.jval.2023.09.931
First page :
Section Title :
Open access? :
No
Section Order :
10421